AstraZeneca: Supernova Phase III Trial of Sipavibart Long-Acting Antibody Met Primary Endpoints in Preventing COVID-19 in Immunocompromised Patient Population
May 17, 2024
May 17, 2024
WILMINGTON, Delaware, May 17 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Positive high-level results from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial showed AstraZeneca's sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID 19 compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromi . . .
Positive high-level results from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial showed AstraZeneca's sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID 19 compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromi . . .